SPL 2.11% 9.3¢ starpharma holdings limited

Ann: Quarterly Cashflow Report, page-3

  1. 2,402 Posts.
    lightbulb Created with Sketch. 629
    An encouraging cash flow report, but by removing the $1.3M Mundipharma payment from customer revenue we see only $200K revenue for other activities. On my analysis Aspen has not yet bought any packaged Fleurstat and the condom market is stalled completely. This $200K can easily be accounted for by product manufactured for DEP partners, as mentioned in the report.

    I look forward keenly to reports in FYE 2019 where the income exceeds the expenditure!
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.